Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
LTGO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Stock-Based Compensation history
Currency unavailable · from the cash flow
No Stock-Based Compensation data reported for this period type.
Stock-Based Compensation vs competitors
How LTGO compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $56.49M USD | +7.4% | +6.1% | 7.7% | |
| LTM Mar 2026 | $41.26M USD | +13.2% | +22.4% | 5.2% | |
| LTM Mar 2026 | $10.16M USD | -34.5% | +43.2% | 30.0% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding LTGO) | — | +7.4% | +22.4% | 7.7% | |
Competitors are the stored peer set for LTGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Latigo Biotherapeutics Inc.
NASDAQ:LTGO
Intrinsic Alpha fair value
Locked
Current Price
$13.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.